Experts discuss the importance of effective patient communication regarding prescription digital therapeutics (PDTs), the need for clinician training prior to PDT implementation, and key considerations for healthcare providers when prescribing these digital interventions.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.
Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.
A renowned expert examines the essential elements for developing successful diabetes quality improvement programs.
Sean M. Oser, MD, MPH, elucidates the critical role of HEDIS measurements in optimizing treatment sequencing for diabetes care.
A leading gastroenterologist highlights her initial thoughts about subcutaneous biologics.
Dr. Seminerio uncovers what excited her about IV biologics when they first came to market.
Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.
Arwen Podesta, MD, examines the role of photodynamic therapies in integrative care and assess how they impact patient outcomes.
Arwen Podesta, MD, details the benefit and safety of prescription digital therapeutics.
Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.
A clinical pharmacy manager provides insights on optimal patient monitoring practices for patients receiving treatment for myelofibrosis.
Sean M. Oser, MD, MPH, discusses how raw CGM data can personalize diabetes treatment.
Sean M. Oser, MD, MPH, describes the role of continuous glucose monitoring (CGM) data in informing the development and implementation of quality measures for diabetes care.
An expert gastroenterologist highlights what her experience has been like with subcutaneous biologics.
Dr. Jennifer Seminerio discusses what what her overall perspective with intravenous biologics in gastrointestinal diseases
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, outlines factors that inform treatment decisions for patients with myelofibrosis, including comorbidities and platelet count.
Dr Mahmoudjafari provides an overview of JAK inhibitors available for the treatment of patients with myelofibrosis.
Sean M. Oser, MD, MPH, provides an in-depth look at the use of analytics in diabetes management.
Sean M. Oser, MD, MPH, opens a discussion surrounding key considerations in diabetes management.
Arwen Podesta, MD, details the therapeutic areas in which prescription digital therapeutics (PDTs) have been studied and show the most promise, as well as some of the unmet needs in patients with mental health conditions that PDTs may be able to address.
Arwen Podesta, MD, defines what prescription digital therapeutics (PDTs) are, describes how they differ from nonprescription digital health tools, and details the FDA review process for PDTs.
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, shares expert perspectives on the important role of risk stratification in determining optimal treatment decisions for patients with low-risk or high-risk myelofibrosis.
An expert on myelofibrosis provides clinical insights on features of the disease that can impact patient quality of life, including splenomegaly, hypertension, and bone pain.
An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.
Dr. Zouzoulas discusses key patient considerations to consider when deciding on an intravenous or subcutaneous biologic.
An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.
